Uploaded image for project: 'eCQM Issue Tracker'
  1. eCQM Issue Tracker
  2. CQM-6100

Statin metric and current clinical practice

XMLWordPrintable

    • Icon: EC eCQMs - Eligible Clinicians EC eCQMs - Eligible Clinicians
    • Resolution: Answered
    • Icon: Moderate Moderate
    • None
    • None
    • Neelima Kale
    • 2162878686
    • Hide
      Thank you for your question about the clinical quality measure CMS347v6, Statin Therapy for the Prevention and Treatment of Cardiovascular Disease. Population 3 for v6 of the measure is defined as follows:

      "Patients Age 40 to 75 Years with Diabetes without ASCVD or LDL Greater than 190 or Hypercholesterolemia" and exists "Qualifying Encounter during Measurement Period."

      For all patients with diabetes and age 40-75 years, the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol require at least a moderate-intensity statin. Patients younger than 40 years with diabetes would not be included in Population 3. We will consider this suggestion during the upcoming eCQM Annual Update cycle.
      Show
      Thank you for your question about the clinical quality measure CMS347v6, Statin Therapy for the Prevention and Treatment of Cardiovascular Disease. Population 3 for v6 of the measure is defined as follows: "Patients Age 40 to 75 Years with Diabetes without ASCVD or LDL Greater than 190 or Hypercholesterolemia" and exists "Qualifying Encounter during Measurement Period." For all patients with diabetes and age 40-75 years, the 2018 ACC/AHA Guidelines on the Management of Blood Cholesterol require at least a moderate-intensity statin. Patients younger than 40 years with diabetes would not be included in Population 3. We will consider this suggestion during the upcoming eCQM Annual Update cycle.
    • CMS0347v7
    • Ability to satisfy statin metric requirements

      In the measure, CMS347v6, Statin Therapy for the Prevention and Treatment of Cardiovascular Disease, population 3 is defined as having either type 1 or type 2 diabetes, and they pass the measure (included in numerator) if the patient is prescribed a statin. However, according to current guidelines from the both cardiology and endocrinology societies. only those patients with either Type 1 or Type 2 diagnosis AND and ASCVD risk >= 7.5% should be on a statin. This a large number of younger diabetic patients do not need a statin and fail this measure inappropriately. Is there a proposed fix to this dilemma? Should patients with an ASCVD risk less than 7.5% be excluded from population 3 for this metric?

            edave Mathematica EC eCQM Team
            NeelimaKale Neelima Kale (Inactive)
            Votes:
            0 Vote for this issue
            Watchers:
            2 Start watching this issue

              Created:
              Updated:
              Resolved:
              Solution Posted On: